Search
Lolium perenne pollen
go.drugbank.com/drugs/DB10389ApprovedLolium perenne pollen is mainly used in allergenic testing.
Trypsin
go.drugbank.com/drugs/DB11237ApprovedInvestigationalVet approvedTrypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. … When converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine
Lanthanum carbonate
go.drugbank.com/drugs/DB06792ApprovedIt is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733]
Acebutolol
go.drugbank.com/drugs/DB01193ApprovedInvestigationalA cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. … The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Synonyms: N-(3-acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamideIron sucrose
go.drugbank.com/drugs/DB09146ApprovedInvestigationalDue to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients. … Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis
Doxapram
go.drugbank.com/drugs/DB00561ApprovedInvestigationalVet approved(From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
International brands: Dai Er SongAnthoxanthum odoratum pollen
go.drugbank.com/drugs/DB10404ApprovedAnthoxanthum odoratum pollen is mainly used in allergenic testing.
Hexylcaine
go.drugbank.com/drugs/DB00473ApprovedWithdrawnHexylcaine has been discontinued in the US market. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Ketazolam
go.drugbank.com/drugs/DB01587ApprovedWithdrawnKetazolam is not approved in Canada or America.